| Date | Title | Description |
| 18.09.2026 | Healthcare’s Semantic AI Blind Spot: Why LLMs Cannot Replace Deterministic Data Infrastructure | Glynn Dennis, PhD, Chief Science Officer, Kythera Labs
Healthcare AI has reached an inflection point. AI is rapidly moving from isolated demonstrations to production systems embedded in clinical, operational, and research workflows. A new g... |
| 17.09.2026 | ‘We prefer the US’: Revolut’s Storonksy confirms plan for dual US-UK listing | Revolut founder Nik Storonsky has confirmed that the bank is exploring a dual listing in New York and London, adding that he “prefers” the US market.
The chief executive of the UK’s biggest fintech said he could not afford to miss out on a ... |
| 17.09.2026 | Advanced AI Society Joins the Linux Foundation, Launches Open Verification Ecosystem as Congress Moves on Agent Security | New York, NY, September 17th, 2026, TechnologyWire
As bipartisan legislation demands verifiable agent controls, the Advanced AI Society releases the Proof-of-Control v1.0 draft for public comment and hosts “Who’s Watching the Machines?” eve... |
| 17.09.2026 | AstraZeneca зарегистрировала в России новый препарат от гипертензии | AstraZeneca зарегистрировала в России новый препарат от гипертензии
Минздрав зарегистрировал «Баксфенди» (МНН баксдростат) для лечения артериальной гипертензии. Препарат разработан AstraZeneca и относится к новому классу ингибиторов альдост... |
| 17.09.2026 | Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR | — Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company —
TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinic... |
| 15.09.2026 | Rocco Forte Hotels’ Russian outpost pays out bumper dividend | The ring-fenced Russian arm of Rocco Forte Hotels has paid its shareholders a dividend worth more than £3m, despite the luxury hospitality chain being accused of bankrolling Putin’s war machine in Ukraine by maintaining operations in Russia... |
| 14.09.2026 | Pediatric Vaccines Market Expected to Reach USD 56.06 Billion by 2031 as Immunization Programs and Multivalent Vaccines Expand | Pediatric Vaccines Market Overview
According to Mordor Intelligence, the Pediatric Vaccines Market Size was valued at USD 40.24 billion in 2025 and is estimated to grow from USD 42.53 billion in 2026 to reach USD 56.06 billion by 2031, at a... |
| 04.09.2026 | Trump and Kennedy’s health industry deals haven’t been enforced and are at risk of vanishing | Getting your Trinity Audio player ready...
By Stephanie Armour, KFF Health News
In the thick of his competitive reelection race in Michigan, Republican Rep. Tom Barrett joined Health and Human Services Secretary Robert F. Kennedy Jr. at a s... |
| 02.09.2026 | Owkin signs AI drug discovery deal with Boehringer for cancer, immunology | Sept 2 : AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-... |
| 01.09.2026 | Admission to Trading - €2.55 billion bond offering | Admission to Trading - €2.55 billion bond offering
Tue, Sep 01, 2026 12:00 CET Report this content
1 September 2026
Admission to Trading - €2.55 billion bond offering
In accordance with the Financial Conduct Authority's Prospectus Rules: Ad... |
| 01.09.2026 | Admission of Further Securities to Trading | Admission of Further Securities to Trading
Tue, Sep 01, 2026 16:05 CET Report this content
1 September 2026
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
The following notification is made in accordance with The Pu... |
| 01.09.2026 | Sun Pharma signs deal with US government to reduce drug prices | Drug major Sun Pharmaceutical Industries has signed a deal with the US government to lower prices of its innovative drugs in the US, in line with the lowest prices paid by other developed nations, under the most favoured nation (MFN) pricin... |
| 01.09.2026 | AstraZeneca completes agreement for Zegfrovy | AstraZeneca completes agreement for Zegfrovy
Tue, Sep 01, 2026 08:05 CET Report this content
01 September 2026
AstraZeneca completes global license agreement
for oral EGFR inhibitor Zegfrovy for lung cancer
AstraZeneca today announced the s... |
| 01.09.2026 | Directorate change | Directorate change
Tue, Sep 01, 2026 08:10 CET Report this content
1 September 2026
Non-Executive Board Appointment
AstraZeneca PLC announced today that Wan Ling Martello has been appointed as Non-Executive Director with effect from 1 Septe... |
| 01.09.2026 | Enhertu approved in EU for 1L HER2-positive mBC | Enhertu approved in EU for 1L HER2-positive mBC
Tue, Sep 01, 2026 08:30 CET Report this content
01 September 2026
Enhertuplus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients wi... |
| 01.09.2026 | Tagrisso + Orpathys improved PFS in 1L EGFRm lung | Tagrisso + Orpathys improved PFS in 1L EGFRm lung
Tue, Sep 01, 2026 08:00 CET Report this content
1 September 2026
Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free ... |
| 31.08.2026 | AstraZeneca new partner to WIN WIN Award | AstraZeneca new partner to WIN WIN Award
Mon, Aug 31, 2026 08:56 CET Report this content
Sweden's largest sustainability prize gains a new funding partner as AstraZeneca joins WIN WIN Award. The partnership strengthens WIN WIN Award's capac... |
| 28.08.2026 | BioCryst is profitable. Now it wants to buy more rare disease drugs | BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals.
As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly steppi... |
| 28.08.2026 | As it happened: FTSE 100 jumps as oil falls back; Warsh says ‘work to do’ on inflation | Welcome back to the City AM FTSE 100 liveblog.
The UK’s blue-chip index extended gains on Friday after some pressures in the oil market eased off.
Oil prices reared back up on Thursday night, reversing days of losses earlier in the week. Th... |
| 28.08.2026 | China’s InnoCare Pharma Turns a Profit in First Half on Surging Overseas Licensing Revenue | (Yicai) Aug. 28 -- Chinese drugmaker InnoCare Pharma swung into the black in the first half of the year, buoyed by rapid revenue growth from overseas licensing deals.
InnoCare had a net profit of CNY239.7 million (USD35.7 million) in the si... |
| 27.08.2026 | Countdown to BIOHK2026: World-Class Biotech Convention Prepares to Host Global Pavilions, Multi-Track Forums, and Signature Executive Networking | HONG KONG, Aug. 27, 2026 /PRNewswire/ -- As a premier global landmark in biotech, BIOHK2026 convenes international biotech hubs, cross-disciplinary industry forums, and high-impact networking events to accelerate cross-border partnerships i... |
| 27.08.2026 | Tezspire CROSSING trial met primary endpoints | Tezspire CROSSING trial met primary endpoints
Thu, Aug 27, 2026 08:15 CET Report this content
27 August 2026
Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints... |
| 25.08.2026 | AstraZeneca prices a €2.55 billion bond offering | AstraZeneca prices a €2.55 billion bond offering
Tue, Aug 25, 2026 08:00 CET Report this content
25 August 2026
AstraZeneca prices €2.55 billion bond offering
AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned... |
| 19.08.2026 | Alpro Group and AstraZeneca Collaborate to Advance Early Detection Across the Cardio-Kidney-Metabolic Spectrum and Raise Awareness of Hyperkalemia | Nationwide #AreYourKidneysOK+? initiative expands access to subsidised blood screening, public education, and pharmacist support for 12,550 Malaysians.
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 19 August 2026 – As chronic condition... |
| 19.08.2026 | Director/PDMR Shareholding | Director/PDMR Shareholding
Wed, Aug 19, 2026 12:00 CET Report this content
19 August 2026
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 17 August 2026, an award of the Company... |
| 19.08.2026 | Tracker funds are turning 50 – will they make it to 100? | Vanguard launched its first ever tracker fund 50 years ago this month. Since then, they have had an enormous impact on the way our capital markets function – and now make up more than half all fund-held assets. Ali Lyon asks: will they be a... |
| 19.08.2026 | BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment | BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones.
Alesta Therapeutic’s lead drug is a potential treatment for hypophosphatasia (HPP).
The deal bolsters BioMarin’s u... |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования
«Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 18.08.2026 | The startup using AI to help rare disease families develop custom treatments | Nome is building an AI-powered drug development service for ultra-rare disease patients, helping families identify potential treatments and map out a path from diagnosis to clinical development.
The startup targets patient groups often over... |
| 18.08.2026 | Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer | Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
Tue, Aug 18, 2026 10:35 CET Report this content
OSLO, Norway, 18 August 2026 – Lytix Biopharma ASA (“Lytix” or the “Com... |
| 17.08.2026 | Tagrisso+Orpathys improved PFS & OS in EGFRm lung | Tagrisso+Orpathys improved PFS & OS in EGFRm lung
Mon, Aug 17, 2026 08:00 CET Report this content
17 August 2026
Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful
improvements in progression-free an... |
| 17.08.2026 | Update on eVOLVE-Lung02 Phase III trial | Update on eVOLVE-Lung02 Phase III trial
Mon, Aug 17, 2026 08:05 CET Report this content
17 August 2026
Update on eVOLVE-Lung02 Phase III trial of volrustomig
plus chemotherapy in metastatic non-small cell lung cancer
AstraZeneca is disconti... |
| 17.08.2026 | Enhertu improved PFS in 1L HER2m lung cancer | Enhertu improved PFS in 1L HER2m lung cancer
Mon, Aug 17, 2026 08:30 CET Report this content
17 August 2026
Enhertu demonstrated statistically significant and clinically meaningful improvement in
progression-free survival as 1st-line treatm... |
| 14.08.2026 | Включение новых препаратов в ЖНВЛП сэкономило бюджету 2 млрд рублей | Включение новых препаратов в ЖНВЛП сэкономило бюджету 2 млрд рублей
Включение восьми новых препаратов в перечень жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП) позволило сэкономить бюджету 2 млрд руб. в первом полугодии 2... |
| 14.08.2026 | Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving Growth | The pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play... |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview
According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 11.08.2026 | Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio | Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million.
Deal centers around Actio’s lead drug for KCNT+ epilepsy, ABS-1230.
The deal expands Jazz’s rare epilepsy portfolio, with ABS-1230 recently accepted into an FDA pro... |
| 10.08.2026 | The power of genetic testing: new screening methods are catching rare diseases before symptoms start | Genetic testing is helping rare disease patients get answers earlier, sometimes before symptoms appear, opening the door to treatment before irreversible damage occurs.
For families, a genetic diagnosis can provide much more than a name for... |
| 10.08.2026 | Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma | Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Mon, Aug 10, 2026 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)... |
| 07.08.2026 | Three Swiss biotechs widen their reach into pharma, paediatrics and lung disease |
SOPHiA GENETICS, a Rolle (VD)-based genomics company founded in 2011, runs SOPHiA DDM, a cloud platform that analyses genomic and multimodal data for hospitals, laboratories and biopharma partners. The company reported second-quarter reven... |
| 07.08.2026 | По каким еще лекарствам приняла решение комиссия Минздрава | По каким еще лекарствам приняла решение комиссия Минздрава
Поддержано включение в перечень ЖНВЛП мосунетузумаба — инновационного онкогематологического препарата, применяемого у взрослых с рецидивирующей или рефрактерной фолликулярной лимфом... |
| 06.08.2026 | Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas | A select group of private companies including Astrazeneca and Jaguar Land Rover will be able to endorse migrants to enter the UK on a skilled talent visa for the first time.
The list of over 100 companies, which also includes GSK, Arm and a... |
| 06.08.2026 | AstraZeneca may buck a decade of pharma strategy to buy U.S. scale | Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb’s U.S.-centric business, but at the cost of slower growth and integration risk.
The reports had the industr... |
| 06.08.2026 | Virtualization isn't broken. It's overdue for reinvention. | Enterprise infrastructure is entering a new era. After nearly two decades as one of IT's most dependable foundations, virtualization now sits at the center of a bigger question: How should enterprises build the operating model they need for... |
| 06.08.2026 | CAMP4 advances rare disease treatment for SYNGAP1 into human trials | CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders.
The trial will enroll at least 30 children ages 2 to 18 and use a... |
| 05.08.2026 | Pharma Giants Eye Colossal Merger: AstraZeneca and Bristol Myers Squibb in $400 Billion Talks | AstraZeneca and Bristol Myers Squibb reportedly discuss a $400 billion pharmaceutical megamerger. This potential tie-up would reshape the industry. The news sent AstraZeneca shares down, puzzling market analysts. Many question the strategic... |
| 04.08.2026 | Акции AstraZeneca упали на 9% после сообщений о сделке с BMS | Акции AstraZeneca упали на 9% после сообщений о сделке с BMS Инвесторы не увидели очевидных преимуществ возможного объединения
Инвесторы британо-шведской фармкомпании AstraZeneca негативно восприняли сообщения о возможной покупке американск... |
| 03.08.2026 | AstraZeneca slides after report of Bristol Myers merger talks leaves analysts ‘perplexed’ | AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal.
If completed, a combined company could be valued at roughly roughly $400 billion.
Analysts were puzzled by both the news itself, as well as the timing o... |
| 03.08.2026 | Admission of Further Securities to Trading | Admission of Further Securities to Trading
Mon, Aug 03, 2026 16:05 CET Report this content
3 August 2026
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
The following notification is made in accordance with The Publi... |
| 03.08.2026 | CNBC Daily Open: Markets exhale as Trump steps back, OPEC+ steps up | Trump canceled a planned attack on Iran, saying the “perimeters of a deal” had been agreed.
OPEC+ approved a September output increase of about 188,000 barrels a day.
Oil prices retreated sharply, unwinding gains built on months of conflict... |
| 03.08.2026 | Dow hits fresh record as oil prices tumble | NEW YORK: Oil prices slumped and stocks mostly rose Monday (Aug 3) after US President Donald Trump insisted negotiations with Iran were ongoing despite Tehran's denials.
Crude futures slid more than four per cent as markets brushed aside Ir... |
| 03.08.2026 | Британская AstraZeneca обсуждала с американской Bristol Myers Squibb слияние стоимостью почти $400 млрд | Британская фармацевтическая компания AstraZeneca и американская Bristol Myers Squibb (BMS) провели предварительные переговоры о возможном слиянии, которое может привести к созданию одного из крупнейших производителей лекарств в мире с совок... |
| 03.08.2026 | Astrazeneca share price tumbles on $400bn megamerger talks | Astrazeneca’s share price slumped sharply on Monday as investors baulked at a potential $400bn megamerger with US rival Bristol Myers Squibb.
Shares in the UK drugmaker slid six per cent in early trading to 11,866p after the Financial Times... |
| 03.08.2026 | Astrazeneca explores $400bn megadeal with US rival | Astrazeneca is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb, in a deal that would create one of the world’s largest pharmaceutical groups.
The FTSE 100 giant has held talks with the US group in recent months about a... |
| 03.08.2026 | Lung Cancer Gene Therapy Takes First Step Toward AI Biomarker Selection | By James Whitaker
Published: Aug 03 2026, 9:43 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 03.08.2026 | Much 'to do' about yen intervention | Previous
Japan's Finance Minister Satsuki Katayama speaks to the media about the U.S.-Japan joint forex action upon her arrival at the Finance Ministry in Tokyo, Japan, August 3, 2026. REUTERS/Issei Kato TPX IMAGES OF THE DAY
A man walks pa... |
| 03.08.2026 | CNBC Daily Open: Back to the negotiating table | Trump said negotiations with Iran will begin Monday after he held off on new strikes.
A U.K. maritime agency reported an explosion in close proximity to a vessel near Khasab, Oman.
Ukrainian officials fear a Russian assault on energy infras... |
| 03.08.2026 | Oil price falls but Trump and Iran clash on negotiations claim | The price of oil has drifted lower after Donald Trump called off strikes on Iran but progress towards a finalised peace deal continues to stall as the President clashes with Iran’s leadership.
Brent crude – the international benchmark for o... |
| 02.08.2026 | AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports | UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times.
The megadeal would be one of the largest in history, creating a combined compa... |
| 02.08.2026 | Stock futures rise in first trading day of August as oil prices slide: Live updates | U.S. equity futures rose early Monday as investors awaited the July jobs report and another busy week of earnings to kick off August trading.
Futures tied to the Dow Jones Industrial Average rallied 333 points, or 0.63%. S&P 500 futures... |
| 02.08.2026 | AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer | By Joshua Mitchell
Published: Aug 02 2026, 5:39 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 31.07.2026 | A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors | Investors are becoming more open to international equities after years of U.S.-heavy portfolios, Janus Henderson Investors’ Julian McManus told CNBC.
McManus said “Magnificent Seven” concentration has left portfolios vulnerable.
The MSCI AC... |
| 31.07.2026 | New Medicaid work rules could cause patients to lose coverage, rare disease advocates warn | New Medicaid work requirements could put rare disease patients at risk of losing coverage, even when their medical conditions prevent them from consistently working.
Advocates warn that vague exemption rules and differing state policies cou... |
| 31.07.2026 | Datroway approved in EU for TNBC | Datroway approved in EU for TNBC
Fri, Jul 31, 2026 08:48 CET Report this content
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic T... |
| 30.07.2026 | Qureight Secures $20M for AI-Powered Clinical Trials | Qureight secured $20 million in Series B funding. Molten Ventures led the round, joined by existing investors. This capital fuels Qureight's AI-powered imaging platform. It targets lung and heart clinical trials. The technology accelerates ... |
| 29.07.2026 | Qureight Raises $20M for AI-powered Lung and Heart Clinical Trials | Qureight just raised $20 million to fix how to read a chest scan. The Cambridge company builds AI imaging tools for lung and heart clinical trials, and its Series B was led by Molten Ventures, with backers Hargreave Hale AIM VCT, XTX Ventur... |
| 28.07.2026 | Sweeping job cuts at GSK to fund £400m Cambridge campus | GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge, in a move it hopes will bolster its drugs pipeline anFd stave off a looming patent cliff-edge.
In his first major update as chief executive, Luk... |
| 27.07.2026 | AstraZeneca Q2 Earnings Beat Analysts as Cancer Drugs Carry $80B Target | By Jerry Owens
Published: Jul 27 2026, 10:32 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 27.07.2026 | Update on Ultomiris Phase III trial in HSCT-TMA | Update on Ultomiris Phase III trial in HSCT-TMA
Mon, Jul 27, 2026 08:10 CET Report this content
27 July 2026
Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell tra... |
| 27.07.2026 | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o... |
| 27.07.2026 | Sone-Ve improved survival in gastric cancers | Sone-Ve improved survival in gastric cancers
Mon, Jul 27, 2026 08:05 CET Report this content
27 July 2026
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd a... |
| 24.07.2026 | Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 24, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 23.07.2026 | 2026 Rally® Awards™ Recognize the Teams Redefining Recruitment Marketing and Employer Branding | Winners across 18 categories reflect the modern talent attraction practices reshaping how employers compete for and win top talent
BOSTON, July 23, 2026 /PRNewswire-PRWeb/ -- Rally® Recruitment Marketing today announced the winners of the 2... |
| 23.07.2026 | Etcamah approved in the EU for ER+ breast cancer | Etcamah approved in the EU for ER+ breast cancer
Thu, Jul 23, 2026 08:25 CET Report this content
23 July 2026
Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer
A... |
| 22.07.2026 | Neurimmune closes licensing deal of up to USD425 million |
Cliramitug is an investigational human monoclonal antibody discovered by Neurimmune and designed to deplete amyloid deposits from affected hearts in patients with amyloid transthyretin cardiomyopathy (ATTR-CM). In 2022, Neurimmune entered ... |
| 21.07.2026 | HR Asia Recognizes Vietnam's Best Companies to Work for in 2026 Amidst Complex Labor Challenges | HO CHI MINH CITY, Vietnam, July 21, 2026 /PRNewswire/ -- The HR Asia Best Companies to Work for in Asia 2026 Vietnam awards organised by Business Media International have officially recognized the nation's 109 outstanding companies. This ye... |
| 20.07.2026 | PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing | ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for... |
| 17.07.2026 | Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform | Targets Japan and Singapore as Part of Broader Asia Expansion
TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcas... |
| 15.07.2026 | AstraZeneca Pays $600M for Oral Pill That Beat Chemo in Rare Lung Cancer | By Philip Nickell
Published: Jul 15 2026, 4:46 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 15.07.2026 | AstraZeneca Licenses Zegfrovy From Dizal In Deal Worth Up To $1.5 Billion | AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical for Zegfrovy, an oral targeted therapy approved in the U.S. and China for certain patients with non-small cell lung cancer.
Under the agreement, ... |
| 14.07.2026 | Jane Goodall Institute USA and FormationQ Launch First-of-its-kind Quantum Computing Research Programme to Explore the Ecological Roots of War and Peace | LONDON and AUSTIN, Texas, July 14, 2026 /PRNewswire/ -- The Jane Goodall Institute (JGI) USA and FormationQ today announced a landmark research partnership that will apply trapped-ions quantum computing by IonQ to one of the most enduring q... |
| 14.07.2026 | AstraZeneca licenses novel EGFR inhibitor | AstraZeneca licenses novel EGFR inhibitor
Tue, Jul 14, 2026 08:00 CET Report this content
14 July 2026
AstraZeneca enters exclusive global license agreement for novel oral
EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
Co... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 12.07.2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical giant's ... |
| 11.07.2026 | AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable? | AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years.
Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was... |
| 10.07.2026 | Stocks shrug off tensions to rise on renewed tech interest | NEW YORK: Global stock markets were largely positive on Thursday (Jul 9) as investors rediscovered their appetite for tech names and brushed off a new volley of strikes between the United States and Iran, with oil prices falling slightly.
I... |
| 09.07.2026 | AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse | AstraZeneca’s medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition.
Shares slumped and were on track for the worst day in over six years.
Jefferies analysts s... |
| 09.07.2026 | Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more | - |
| 09.07.2026 | Gene-Silencing Drug Wainua Fails Landmark ATTR-CM Trial in AstraZeneca Setback | By John Bright
Published: Jul 09 2026, 11:18 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 08.07.2026 | Daily Stock Market Live
Stocks gain as chipmakers rise, oil prices fall: Live updates | Stocks rose on Thursday, supported by a jump in semiconductors and a fall in oil prices, as equity markets tried to recover despite renewed U.S.-Iran tensions.
The Nasdaq Composite gained 1.2%, while the S&P 500 rose 0.8%. The Dow Jones... |
| 08.07.2026 | Genesys University Seed Fund Holds First Close With Over $30 Million In Commitments | The University of Toronto, McMaster University, Venture Ontario, and Genesys Capital announced the creation of a new early-stage life sciences venture capital fund. The Genesys University Seed Fund has held a first close representing over $... |
| 07.07.2026 | BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong - Connecting Global Leaders in Biotechnology | Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.
HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong Kong International Biotechnology Conferenc... |
| 06.07.2026 | Онкопациенты выше всего оценили репутацию Roche, AstraZeneca и Novartis | Онкопациенты выше всего оценили репутацию Roche, AstraZeneca и Novartis
Исследовательская компания PatientView представила ежегодный рейтинг репутации фармкомпаний в онкологии. В нем 505 пациентских организаций из разных стран, работающих в... |
| 02.07.2026 | Группе компаний ICL – 35 лет: от завода ЭВМ до лидера отечественной ИТ-индустрии в производстве, ПО и сервисах | 2 июля 1991 года началась история ГК ICL – одного из лидеров современной российской ИТ-отрасли. Юбилей группа компаний встречает с расширенной линейкой собственных программных продуктов, заводом мощностью до 1 млн изделий в год и стратегией... |
| 02.07.2026 | Building on strong commercial momentum, Sonar launches new products to improve agentic effectiveness |
Agents are limited by what they don't know. They fall down when they lack the context of architecture, security and quality standards, approved libraries, an organization's conventions, and so on. Left ungoverned, they produce code that wo... |
| 02.07.2026 | Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSC... | SHANGHAI, July 2, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/N... |
| 01.07.2026 | Admission of Further Securities to Trading | Admission of Further Securities to Trading
Wed, Jul 01, 2026 16:05 CET Report this content
1 July 2026
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
The following notification is made in accordance with The Public ... |
| 29.06.2026 | WorkBoard Extends its Strategy Execution Platform with new AI-Native Strategic Portfolio Management Solution and Portfolio Analyst Agents | WorkBoard Inc., provider of the leading enterprise strategy execution and OKR platform, WorkBoardAI, today announced the launch of its Strategic Portfolio Management (SPM) solution, the market’s first truly AI-native SPM.
This press release... |
| 29.06.2026 | Datroway recommended for approval in EU for TNBC | Datroway recommended for approval in EU for TNBC
Mon, Jun 29, 2026 08:00 CET Report this content
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast canc... |
